This topic contains a solution. Click here to go to the answer

Author Question: Relying on clinical findings for the treatment of ventilator-associated pneumonia may do which of ... (Read 74 times)

go.lag

  • Hero Member
  • *****
  • Posts: 667
Relying on clinical findings for the treatment of ventilator-associated pneumonia may do which of the following?
 
  a. Decrease the morbidity of VAP.
  b. Decrease the mortality of VAP.
  c. Create multidrug-resistant organisms.
  d. Reduce the need for invasive microbio-logic procedures.

Question 2

The initial empiric antibiotic used to treat suspected methicillin-resistant Staphylococcus aureus in a patient with late-onset VAP is which of the following?
 
  a. Linezolid
  b. Gentamicin
  c. Tobramycin
  d. Ciprofloxacin



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

isabelt_18

  • Sr. Member
  • ****
  • Posts: 342
Answer to Question 1

ANS: C
Relying on clinical findings alone can result in unnecessary use of broad-range antibiotics, which in turn can lead to the emergence of multidrug-resistant strains of microorganisms.

Answer to Question 2

ANS: A
According to Table 14-2, patients with late-onset VAP who develop MRSA should be treated with linezolid or vancomycin.





 

Did you know?

More than one-third of adult Americans are obese. Diseases that kill the largest number of people annually, such as heart disease, cancer, diabetes, stroke, and hypertension, can be attributed to diet.

Did you know?

Your heart beats over 36 million times a year.

Did you know?

The Babylonians wrote numbers in a system that used 60 as the base value rather than the number 10. They did not have a symbol for "zero."

Did you know?

Elderly adults are at greatest risk of stroke and myocardial infarction and have the most to gain from prophylaxis. Patients ages 60 to 80 years with blood pressures above 160/90 mm Hg should benefit from antihypertensive treatment.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library